Ardelyx

Ardelyx

Pharmaceuticals
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

$751.6M

Market Cap • 11/5/2026

2007

(19 years)

Founded

2014

(12 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

4,6

P/S

1,6

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,7

EPS

—

Market Cap

Market Cap

751,6M

EV

722,6M

EV/Revenue

1,5

EV/EBITDA

-21,9

EV/EBIT

-20

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-1,1%

Total Yield

-1,1%

Payout

0%

Retained Earnings

-1B

Profitability

Gross Margin

94,5%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

20,1%

Capex/Revenue

0,1%

Capex/D&A

14,5%

Capex/OCF

-2,9%

SBC/OCF

—

% PPE

0,9%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

112,2%

CAGR Op. Income 5Y

-24,5%

CAGR Net Income 5Y

-18,1%

CAGR EPS 5Y

-31,5%

CAGR OCF 5Y

-34,7%

Leverage

N.D./EBITDA

0,9

Debt/Equity

0%

Current Ratio

3,5

Quick Ratio

3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium